Washington Trust Bank Sells 450 Shares of AbbVie Inc. $ABBV

Washington Trust Bank lowered its holdings in AbbVie Inc. (NYSE:ABBV) by 4.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,757 shares of the company’s stock after selling 450 shares during the quarter. Washington Trust Bank’s holdings in AbbVie were worth $1,997,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Achmea Investment Management B.V. raised its position in shares of AbbVie by 1.2% in the second quarter. Achmea Investment Management B.V. now owns 358,572 shares of the company’s stock valued at $66,558,000 after buying an additional 4,327 shares during the last quarter. Golden State Wealth Management LLC lifted its holdings in AbbVie by 23.7% in the second quarter. Golden State Wealth Management LLC now owns 2,627 shares of the company’s stock valued at $488,000 after acquiring an additional 503 shares during the last quarter. HORAN Wealth LLC purchased a new position in AbbVie in the second quarter worth approximately $2,977,000. SouthState Corp grew its position in AbbVie by 0.6% in the second quarter. SouthState Corp now owns 78,093 shares of the company’s stock worth $14,496,000 after acquiring an additional 451 shares during the period. Finally, Andra AP fonden increased its stake in AbbVie by 3.3% during the second quarter. Andra AP fonden now owns 74,800 shares of the company’s stock worth $13,884,000 after acquiring an additional 2,400 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on ABBV shares. Bank of America increased their price target on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Erste Group Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Daiwa America raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 7th. Piper Sandler reaffirmed an “overweight” rating and set a $289.00 price objective (up previously from $284.00) on shares of AbbVie in a research report on Wednesday. Finally, Hsbc Global Res lowered AbbVie from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and an average target price of $238.05.

AbbVie Stock Performance

Shares of AbbVie stock opened at $216.96 on Thursday. The business has a 50-day simple moving average of $222.84 and a 200-day simple moving average of $201.84. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. AbbVie Inc. has a one year low of $163.81 and a one year high of $244.81. The company has a market cap of $383.27 billion, a PE ratio of 103.31, a P/E/G ratio of 1.42 and a beta of 0.50.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the previous year, the firm earned $3.00 earnings per share. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. AbbVie’s dividend payout ratio is 524.24%.

Insider Transactions at AbbVie

In other AbbVie news, EVP Azita Saleki-Gerhardt sold 42,370 shares of AbbVie stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the transaction, the executive vice president owned 177,292 shares of the company’s stock, valued at $35,178,278.64. The trade was a 19.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.25% of the stock is owned by corporate insiders.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.